Quantcast

Latest Quinazolines Stories

2009-04-01 08:00:00

LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib). If approved, TYVERB(R)/TYKERB(R) could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States. The variation to the EU marketing authorization and...

2008-12-04 12:39:59

A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say. The study, published in the journal Clinical Cancer Research, found the oral chemotherapy drug lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer, or those who express EGRF alone, derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent...

af7cb6fe1aa746fdbe430814fe2c7b311
2008-11-21 12:27:27

A recent study suggests that advanced lung cancer patients might be able to avoid another chemotherapy treatment by taking a targeted pill treatment. An international study showed patients on Iressa, an expensive, newer targeted treatment, survived about as long as those on another course of chemotherapy. "This will provide us with another drug in our armory," said Dr. Michael Seckl, head of Cancer Research UK's Lung Cancer Group at Imperial College in London. Seckl was not connected to the...

2008-11-07 12:00:23

Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. Saturn is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled...

2008-11-07 03:00:04

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. There were no new or unexpected safety signals in the study and adverse...

2008-10-23 15:00:28

U.S. scientists say an early trial of a multi-kinase inhibitor has shown impressive tumor shrinkage in patients with a hard-to-treat form of thyroid cancer. Assistant Professor Pasi Janne of Harvard University Medical School and Professor Steven Sherman of the M.D. Anderson Cancer Center said the encouraging results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial. The compound, XL184, targets cell growth and migration, as...

2008-10-12 18:00:07

A GRANDMOTHER with terminal cancer who faced moving to get life- saving drugs on the NHS has won her battle with Midland health bosses to receive her medication. Carol Rummels, from Stoke Lodge, in Bristol, considered moving to Scotland so she could continue to take the drug Tarceva. Doctors had given the 61 year-old just two months to live after diagnosing with brain and lung cancer last summer. But after taking the drug the tumours shrank, prolonging her life by another 12 months....

2008-10-12 18:00:07

A GRANDMOTHER with terminal cancer who faced moving to Scotland to get life-saving drugs free on the NHS has won her battle with health bosses in England to fund the medication that is keeping her alive. The landmark ruling means that other cancer sufferers in the area that may benefit from the drug will now be given Tarceva on the NHS. Carol Rummels, from Stoke Lodge, in Bristol, was given just two months to live after being diagnosed with brain and lung cancer last summer but after...

2008-10-06 21:00:15

By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer. The trial focused on patients who had not responded to chemotherapy. But patients who were treated with Avastin and Tarceva did not survive significantly longer than those who were...

2008-10-06 15:00:41

Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer. However, there may still be a future for the drug combination within this indication, assuming data from a Phase III trial in the maintenance setting prove more positive. The Phase III study, known as BeTa Lung, was a randomized, double blinded study comparing the second-line combination of Avastin...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin